6IPO Recognition Bonus

Following the successful IPO, Draupnir Holding B.V (as the selling shareholder) granted and funded (or reimbursed, as the case may be) a bonus to eligible members of the Board of Directors and the Executive Committee as well as other eligible employees and a former director of PolyPeptide Laboratories Holding B.V. (the Group’s predecessor holding company) in recognition of their past efforts to the Group. The IPO Recognition Bonus was paid in cash; however, eligible members of the Board of Directors, the Executive Committee and certain other senior managers received 50% of their IPO Recognition Bonus in shares.

The EGM 2021 approved the IPO Recognition Bonus in a cumulative amount of EUR 7.0 million (excluding social security costs, etc.), of which the following amounts set forth in the table below were paid and/or granted to eligible members of the Board of Directors and the Executive Committee as well as other eligible employees and a former director of PolyPeptide Laboratories Holding B.V. (the Group’s predecessor holding company). All costs, including additional associated costs (e.g., social security contributions), were fully reimbursed by Draupnir Holding B.V. (i.e., the Company did not incur any costs or make any additional contributions in association with the IPO Recognition Bonus).

Table 14:
IPO Recognition Bonus paid / granted by Draupnir Holding B.V.

EUR

Cash compensation

Share-based compensation

Total (cash and shares)

Social security and other contributions 5

Total IPO Recognition Bonus

 

 

 

 

 

 

Erik Schropp 1

185,000

185,000

370,000

370,000

Jane Salik 2

1,000,000

1,000,000

2,000,000

17,608

2,017,608

Jan Fuhr Miller 3

450,000

450,000

900,000

7,924

907,924

Jan Christensen 3

450,000

450,000

900,000

460,884

1,360,884

Daniel Lasanow 3

450,000

450,000

900,000

477,770

1,377,770

Other employees 4

1,485,000

445,000

1,930,000

516,818

2,446,818

Total

4,020,000

2,980,000

7,000,000

1,481,004

8,481,004

1 Erik Schropp previously served as a member of the board of directors of PolyPeptide Laboratories Holding B.V. (the Group’s predecessor holding company). Erik Schropp is also a member of the Company’s current Board of Directors. For further information, see section 4.2 “2021 compensation of the Board of Directors” of this Remuneration Report.
2 Jane Salik served as CEO from 1 January 2021 until 29 April 2021 and then as member of the Executive Committee until 17 August 2021. For information regarding her compensation as member of the Board of Directors, see section 4.2 “2021 compensation of the Board of Directors” of this Remuneration Report. For information regarding her compensation related to her services as CEO and member of the Executive Committee during the period from 1 January 2021 to 17 August 2021, see section 5.2.2 “2021 aggregate compensation of the Executive Committee” of this Remuneration Report.
3 Jan Fuhr Miller (CFO), Jan Christensen (Director Global Sales and Marketing until 31 December 2021) and Daniel Lasanow (Director Global Operations). For information regarding their separate compensation as members of the Executive Committee, see section 5.2.2 “2021 aggregate compensation of the Executive Committee” of this Remuneration Report.
4 Consists of 18 other senior managers of PolyPeptide as well as a member of the board of directors of PolyPeptide Laboratories Holding B.V. (the Group’s predecessor holding company), Peter Nilsson, who received EUR 90,000 in cash compensation and EUR 90,000 in share-based compensation.
5 Social contributions and other required contributions.